STOCK TITAN

Glaukos Corporation (NYSE: GKOS) discloses CFO earning 3,660 stock options

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals. These options, with an exercise price of $55.18 per share, are part of an award originally granted in March 2022 and became earned after the company met specified operational targets.

Half of this earned portion will vest and become exercisable in March 2026, with the remaining half vesting in December 2026. After this update and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thurman Alex R.

(Last) (First) (Middle)
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY

(Street)
ALISO VIEJO CA 92656

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $55.18 12/11/2025 A 3,660(1) (2) 03/24/2032 Common Stock 3,660 $0 37,510(3) D
Explanation of Responses:
1. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating & Governance Committee of the Issuer's Board of Directors determined that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.
2. 50% of the portion of the option reported herein will vest and become exercisable in March 2026. 50% of the portion of the option reported herein will vest and become exercisable in December 2026.
3. Amount reported reflects a de minimis adjustment to correct a mathematical error previously reported.
Diana Scherer, Attorney-in-Fact 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Glaukos Corporation (GKOS) report in this filing?

A senior vice president and chief financial officer of Glaukos Corporation reported earning 3,660 stock options that are tied to the company’s operational performance targets.

What is the exercise price of the Glaukos (GKOS) stock options reported?

The reported stock options have an exercise price of $55.18 per share, allowing the officer to buy Glaukos common stock at that price once vested and exercisable.

When do the Glaukos CFO’s performance-based options vest?

For this portion of the award, 50% of the options will vest and become exercisable in March 2026, and the remaining 50% will vest and become exercisable in December 2026.

Are these Glaukos stock options a new grant or part of a prior award?

The 3,660 options represent a portion of an option previously granted on March 24, 2022, which was subject to multi-year operational performance targets that were determined to have been achieved in part.

How many stock options does the Glaukos officer hold after this transaction?

Following the reported transaction and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.

Why was there a de minimis adjustment mentioned in the Glaukos (GKOS) filing?

The filing states that the amount reported reflects a de minimis adjustment to correct a mathematical error previously reported in the officer’s option holdings.
Glaukos Corp

NYSE:GKOS

GKOS Rankings

GKOS Latest News

GKOS Latest SEC Filings

GKOS Stock Data

6.42B
55.55M
3.31%
107.34%
5.9%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ALISO VIEJO